ethyl 2-methoxy-2-phenylacetate | 33224-90-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-methoxy-2-phenylacetate
• 英文别名: Methoxy-phenyl-acetic acid ethyl ester
• CAS: 33224-90-7
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: QZSNWMGZBAOABA-UHFFFAOYSA-N

物化性质

• 沸点：
  82 °C(Press: 2 Torr)
• 密度：
  1.015 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-methoxy-2-phenylacetate 在 platinum(IV) oxide 氢气 、 sodium hydride 、 溶剂黄146 作用下， 25.0 ℃ 、324.05 kPa 条件下， 反应 7.0h， 生成 3-甲氧基-3-苯基-2-哌啶酮
  参考文献：
  名称：

  一些取代的内酰胺和酰胺的合成和抗惊厥活性。

  摘要：

  合成了13种3-苯基-2-哌啶酮衍生物，并评估了其抗惊厥活性。该组中活性最高的化合物包括两种简单的内酰胺，3-羟基-1-甲基-3-苯基-2-哌啶酮和3-甲氧基-3-苯基-2-哌啶酮和两种N-乙氧基羰基内酰胺1-（乙氧基羰基）-3-羟基-3-苯基-2-哌啶酮和1-（乙氧基羰基）-3-甲氧基-3-苯基-2-哌啶酮，它们的抗惊厥活性与丙戊酸相当或更好。还制备了四种相关的无环酰胺，但是它们基本上没有活性作为抗惊厥药。

  DOI：

  10.1021/jm00368a017
• 作为产物：
  描述：

  甲醇 、 2-重氮基-2-苯基乙酸乙酯 在 silver hexafluoroantimonate 、 C₂₉H₃₃AuClN₃O₂ 作用下， 以 氘代氯仿 为溶剂， 以100%的产率得到ethyl 2-methoxy-2-phenylacetate
  参考文献：
  名称：

  Steroid Derived Mesoionic Gold and Silver Mono- and Polymetallic Carbenes

  摘要：

  A two-step synthesis of gold mesoionic carbene complexes containing estrone moieties has been developed. The method uses the methylation of the triazole nucleus, followed by the treatment of the triazolium salt with Ag2O and transmetalation with [AuCl(SMe2)]. Mono-, bi-, tri-, and tetrametallic gold complexes can be obtained depending on the structure of the starting triazolium salts. Tetrametallic gold carbene embedded in a macrocylic stereoidal cavity containing four estrone nuclei has been also prepared. Additionally, the mono- and bimetallic silver carbene complexes containing triazole-steroid ligands have been isolated and characterized. These complexes resulted to be stable and have been characterized by spectroscopic and HRMS techniques. The gold and silver complexes having triazole-steroid ligands are unprecedented in the literature and the method reported here to access to these compounds is easy and efficient. Preliminary results regarding the catalytic activity of some of the gold-carbenes prepared in the insertion of diazoalkanes into alcohols are presented.

  DOI：

  10.1021/acs.inorgchem.5b01524

文献信息

• Aldol–Tishchenko Reaction of α-Oxy Ketones: Diastereoselective Synthesis of 1,2,3-Triol Derivatives
  作者：Roberto Sanz、Carlos Sedano、Cintia Virumbrales、Samuel Suárez-Pantiga

  DOI：10.1055/a-1509-5655

  日期：2021.10

  selectively deprotonated generating an enolate intermediate, which upon treatment with paraformaldehyde undergoes an aldol–Tishchenko reaction, leading to relevant 1,2,3-triol fragments in a totally diastereoselective manner. The excellent stereocontrol in the generation of a quaternary stereocenter is attributed to stereoelectronic effects in the Evans intermediate. This methodology allows overcoming some

  α-氧酮很容易通过常规途径获得，可以选择性地去质子化产生烯醇中间体，在用多聚甲醛处理后发生羟醛-Tishchenko 反应，以完全非对映选择性的方式产生相关的 1,2,3-三醇片段。生成四元立体中心的出色立体控制归因于埃文斯中间体中的立体电子效应。这种方法可以克服我们之前报道的策略的一些限制，基于 α-锂硫苄基醚与酯和多聚甲醛的反应，拓宽了所获得多元醇的范围。该过程的合成应用包括制备新的 dilignol 模型和一些功能化的氧杂环丁烷。
• Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
  申请人：Malecha W. James

  公开号：US20070027184A1

  公开（公告）日：2007-02-01

  Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

  本文披露了如下所述的Formula VII的磺胺类化合物。本文还披露了用于治疗疾病状态的方法和组合物，包括但不限于癌症、自身免疫疾病、组织损伤、中枢神经系统疾病、神经退行性疾病、纤维化、骨疾病、多聚谷氨酰胺重复疾病、贫血、地中海贫血、炎症症状、心血管疾病以及血管生成在发病机制中起作用的疾病，使用本发明的化合物。此外，还披露了调节组蛋白去乙酰化酶（HDAC）活性的方法。
• Chiral N-heterocyclic carbene ligands for asymmetric catalytic oxindole synthesis
  作者：Yi-Xia Jia、J. Mikael Hillgren、Emma L. Watson、Stephen P. Marsden、E. Peter Kündig

  DOI：10.1039/b810858g

  日期：——

  The Pd-catalysed asymmetric intramolecular alpha-arylation of amide enolates containing heteroatom substituents gives chiral 3-alkoxy or 3-aminooxindoles in high yield and with enantioselectivities up to 97% ee when a new chiral N-heterocyclic carbene ligand is used.

  当使用新的手性N-杂环卡宾配体时，Pd催化的含杂原子取代基的酰胺烯酸酯的不对称分子内α-芳基化反应可高收率和高达97％ee的对映选择性，产生手性3-烷氧基或3-氨基氧吲哚。
• Synthesis of 3-Fluorofuran-2(5H)-ones Based onZ/E Photoisomerisation and Cyclisation of 2-Fluoro-4-hydroxybut-2-enoates
  作者：Karel Pomeisl、Jan Čejka、Jaroslav Kvíčala、Oldřich Paleta

  DOI：10.1002/ejoc.200700439

  日期：2007.12

  some (E)- and (Z)-2-fluoroalk-2-enoates prepared from the corresponding 2-hydroxycarbonyl compounds and ethyl 2-(diethoxyphosphoryl)-2-fluoroacetate have been transformed in high conversions into the target 3-fluorofuran-2(5H)-ones by an efficient Z/E photoisomerisation of noncyclisable Z isomers followed by acid-catalysed cyclisation. In contrast, the acid-catalysed deprotection of ethyl (E)- and

  由相应的 2-羟基羰基化合物和 2-(二乙氧基磷酰基)-2-氟乙酸乙酯制备的一些 (E)- 和 (Z)-2-fluoroalk-2-enoates 的混合物已以高转化率转化为目标 3-氟呋喃-2(5H)-ones 通过对不可环化的 Z 异构体进行有效的 Z/E 光异构化，然后进行酸催化环化。相反，乙基 (E)- 和 (Z)-4-[叔丁基（二甲基）甲硅烷氧基]-2-氟-4-苯基丁-2-烯酸酯的酸催化脱保护导致乙烯基氟的置换，提供(E)-2-氧代-4-苯基丁-3-烯酸乙酯。3-氟-4-苯基呋喃-2(5H)-one 转化为 2-[叔丁基（二甲基）甲硅烷氧基]-3-氟-5-甲基呋喃，作为一种新型的氟化结构单元。（© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)
• INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE
  申请人：Payne E. Joseph

  公开号：US20070135438A1

  公开（公告）日：2007-06-14

  Disclosed herein are carbonyl compounds of having the structural formula: or a pharmaceutically acceptable salt, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

  本公开涉及具有以下结构式的羰基化合物：或其药用可接受的盐、酯或前药。本公开揭示了治疗疾病状态的方法和组合物，包括但不限于癌症、自身免疫疾病、组织损伤、中枢神经系统疾病、神经退行性疾病、纤维化、骨疾病、多谷氨酸重复疾病、贫血、地中海贫血、炎症性疾病、心血管疾病以及血管生成在病因中发挥作用的疾病，使用本发明的化合物。此外，还公开了调节组蛋白去乙酰化酶（HDAC）活性的方法。